NIAID awards $15.5m to needle-free dengue vaccine

By Nick Taylor

- Last updated on GMT

Related tags: Immune system, Antibody

Inviragen and PharmaJet have been awarded a $15.5m (€11.1m) contract by the US NIAID to develop a needle-free dengue vaccine.

Development of the needle-free vaccine would provide a more convenient option for travellers and citizens of regions where dengue is endemic. Furthermore, the product would eliminate hazards and costs associated with disposal of needle waste.

To drive development the US National Institute of Allergy and Infectious Diseases (NIAID) has awarded a five-year, $15.5m contract to Inviragen and PharmaJet. Having secured the contract Inviragen and PharmaJet will combine their respective capabilities in vaccines and delivery.

PharmaJet will apply its needle-free system to delivery of DENVax, a tetravalent dengue vaccine developed by Inviragen. The NIAID contract covers preclinical, regulatory filings, manufacturing and clinical testing of the needle-free dengue vaccine.

Preliminary animal model studies using PharmaJet’s injector to deliver DENVax intradermally have shown the combination is safe and induces neutralising antibodies to all four dengue serotypes, said Jorge Osorio, chief scientific officer at Inviragen.

Successful development of the technology will create a needle-free device capable of inducing a neutralising antibody response after one or two doses. Other dengue vaccines can require multiple injections with intervals between each dose.

PharmaJet injector

Administration of the dengue vaccine will use the PharmaJet injector. This delivers liquid medications by using a spring to create a high-speed jet capable of penetrating the skin.

PharmaJet says the device can perform thousands of injections using single-use disposable syringe. The US Food and Drug Administration (FDA) has cleared the device for intramuscular and subcutaneous delivery.

Related topics: Delivery technologies, Ingredients

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers